Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation.
作者信息
Salvatierra Juan, Aomar-Millán Ismael Francisco, Hernández-Quero José
机构信息
Department of Rheumatology, San Cecilio University Hospital, Granada, Spain.
Department of Internal Medicine, San Cecilio University Hospital, Granada, Spain.
出版信息
Lancet Rheumatol. 2021 Apr;3(4):e248. doi: 10.1016/S2665-9913(21)00064-3. Epub 2021 Mar 8.
Abstract
摘要
相似文献
1
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation.对新冠病毒病合并炎症反应过度患者的白细胞介素-1和白细胞介素-6抑制作用
Lancet Rheumatol. 2021 Apr;3(4):e248. doi: 10.1016/S2665-9913(21)00064-3. Epub 2021 Mar 8.
2
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply.新型冠状病毒肺炎合并炎症反应过度患者的白细胞介素-1和白细胞介素-6抑制——作者回复
Lancet Rheumatol. 2021 Apr;3(4):e248-e249. doi: 10.1016/S2665-9913(21)00066-7. Epub 2021 Mar 8.
3
Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.冠状病毒病（COVID-19）中的补体抑制：一种被忽视的治疗选择。
Front Immunol. 2020 Jul 7;11:1661. doi: 10.3389/fimmu.2020.01661. eCollection 2020.
4
Case Report: Myopathy in Critically Ill COVID-19 Patients: A Consequence of Hyperinflammation?病例报告：危重症 COVID-19 患者的肌病：高炎症反应的后果？
Front Neurol. 2021 Jan 29;12:625144. doi: 10.3389/fneur.2021.625144. eCollection 2021.
5
Early experience with anti-interleukin-6 therapy in COVID-19 hyperinflammation.抗白细胞介素-6疗法在新型冠状病毒肺炎过度炎症中的早期经验
Lung India. 2021 Mar;38(Supplement):S119-S121. doi: 10.4103/lungindia.lungindia_568_20.
6
Interleukin-17A Promotes Arginase-1 Production and 2,4-Dinitrochlorobenzene-Induced Acute Hyperinflammation in Human Papillomavirus E7 Oncoprotein-Expressing Skin.白细胞介素-17A促进精氨酸酶-1的产生以及2,4-二硝基氯苯诱导的人乳头瘤病毒E7癌蛋白表达皮肤的急性过度炎症。
J Innate Immun. 2015;7(4):392-404. doi: 10.1159/000374115. Epub 2015 Feb 14.
7
The anti-inflammatory cytokine response characterized by elevated interleukin-10 is a stronger predictor of severe disease and poor outcomes than the pro-inflammatory cytokine response in coronavirus disease 2019 (COVID-19).在 2019 冠状病毒病（COVID-19）中，以白细胞介素-10 升高为特征的抗炎细胞因子反应比促炎细胞因子反应更能预测严重疾病和不良结局。
Clin Chem Lab Med. 2020 Nov 26;59(3):599-607. doi: 10.1515/cclm-2020-1284. Print 2021 Feb 23.
8
Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.托珠单抗治疗新型冠状病毒肺炎患者并发噬血细胞性淋巴组织细胞增生症：一例报告
J Med Case Rep. 2020 Oct 15;14(1):187. doi: 10.1186/s13256-020-02503-9.
9
COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps.新型冠状病毒肺炎与中性粒细胞：细胞因子风暴与中性粒细胞胞外诱捕网的关系
Mediators Inflamm. 2020 Dec 2;2020:8829674. doi: 10.1155/2020/8829674. eCollection 2020.
10
Complement and protection from tissue injury in COVID-19.补体与 COVID-19 中的组织损伤保护
Clin Kidney J. 2020 Oct 4;13(5):734-738. doi: 10.1093/ckj/sfaa196. eCollection 2020 Oct.
本文引用的文献
1
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.白细胞介素-1和白细胞介素-6抑制与COVID-19合并高炎症患者标准治疗的比较：一项队列研究
Lancet Rheumatol. 2021 Apr;3(4):e253-e261. doi: 10.1016/S2665-9913(21)00012-6. Epub 2021 Feb 3.
2
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.阿那白滞素治疗单独使用皮质类固醇激素或托珠单抗治疗重症 COVID-19 肺炎和中度炎症过度患者。一项回顾性队列研究。
Intern Emerg Med. 2021 Jun;16(4):843-852. doi: 10.1007/s11739-020-02600-z. Epub 2021 Jan 5.
3
Anakinra for severe forms of COVID-19: a cohort study.阿那白滞素用于重症新型冠状病毒肺炎：一项队列研究。
Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
4
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.COVID-19 并发严重炎症性呼吸衰竭患者的早期白细胞介素-1 受体阻断。
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18951-18953. doi: 10.1073/pnas.2009017117. Epub 2020 Jul 22.
5
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.在患有新冠肺炎、急性呼吸窘迫综合征和炎症反应过度的患者中使用高剂量阿那白滞素进行白细胞介素-1阻断：一项回顾性队列研究。
Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.
Zotero 插件